Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Granulocyte colony stimulating factor

Y K Nguyen1

  • 1Department of Clinical Pharmacology and Research, Morton Plant Hospital, Clearwater.

The Journal of the Florida Medical Association
|July 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

The dawning of the age of accountability.

The Journal of the Florida Medical Association·1999
Same journal

Physician office-based quality improvement projects. Florida Medical Quality Assurance, Inc.

The Journal of the Florida Medical Association·1998
Same journal

Hyperlipidemia management in patients with cardiovascular and cerebrovascular disease.

The Journal of the Florida Medical Association·1998
Same journal

On the horizon: newly-developed quality improvement projects. Florida Medical Quality Assurance, Inc.

The Journal of the Florida Medical Association·1998
Same journal

Angiotensin converting enzyme inhibitor use in congestive heart failure. Florida Medical Quality Assurance, Inc.

The Journal of the Florida Medical Association·1998
Same journal

Influenza immunization among Medicare beneficiaries enrolled in a health maintenance organization: 1994. Florida Medical Quality Assurance, Inc.

The Journal of the Florida Medical Association·1998
See all related articles

Recombinant human granulocyte colony-stimulating factor (rhGCSF) is a well-tolerated treatment that accelerates neutrophil recovery in patients undergoing chemotherapy or with acute leukemias. Ongoing clinical trials continue to define its expanding role in supportive care.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Recombinant human granulocyte colony-stimulating factor (rhGCSF) has been available for two years.
  • Clinical data are still needed to fully substantiate its applications.
  • Chemotherapy-induced neutropenia is the most studied application.

Purpose of the Study:

  • To review the current clinical applications of rhGCSF.
  • To summarize the safety and efficacy data available for rhGCSF.
  • To discuss the future potential of rhGCSF in clinical practice.

Main Methods:

  • Review of clinical trial data and published literature on rhGCSF.
  • Analysis of safety profiles, including adverse events.
  • Evaluation of efficacy in accelerating neutrophil recovery and cell mobilization.

Related Experiment Videos

Main Results:

  • rhGCSF accelerates neutrophil recovery post-bone marrow transplant.
  • It mobilizes peripheral blood progenitor cells for transplantation.
  • It speeds neutrophil recovery in acute leukemias.
  • rhGCSF is generally well-tolerated, with mild bone pain as the primary side effect.
  • Mild, reversible elevations in liver enzymes and uric acid have been noted.

Conclusions:

  • rhGCSF is an effective supportive care agent in oncology.
  • Its role is expanding as more clinical data become available.
  • Further clinical trials will better define its therapeutic utility.